ClinicalTrials.govpublic full text
Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
chronic kidney disease, autosomal dominant polycystic kidney disease, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 857552
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.